<DOC>
	<DOCNO>NCT00073944</DOCNO>
	<brief_summary>RATIONALE : BCX-1777 may stop growth cancer cell block enzymes necessary growth . PURPOSE : Phase I trial study effectiveness BCX-1777 treating patient refractory cancer .</brief_summary>
	<brief_title>BCX-1777 Treating Patients With Refractory Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose BCX-1777 patient refractory T-cell non-T-cell malignancy . - Determine safety dose-limiting toxicity drug patient . Secondary - Determine pharmacokinetics single oral single multiple IV dose drug patient . - Determine oral bioavailability drug patient . - Determine , preliminarily , antitumor activity drug patient . OUTLINE : This open-label , nonrandomized , dose-escalation , multicenter study . - Courses 1 2 : Patients receive oral BCX-1777 day 1 15* BCX-1777 IV 30 minute day 8* 22* . - Course 3 : Beginning approximately 6 days* completion course 1 2 , patient receive BCX-1777 IV 30 minute daily day 1-5 8-12 ( total 10 dos ) . NOTE : *+/- 1 day Patients stable disease well dose-limiting toxicity ( DLT ) may receive additional 10-dose treatment course ( course 3 ) 10- 16-day drug-free interval . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos BCX-1777 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience DLT . Patients follow 14 30 day . PROJECTED ACCRUAL : A total 3-24 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Hematologic malignancy refractory least 1 prior curative treatment Nonhematologic tumor refractory least 2 prior therapy , without measurable disease , include follow : Gastrointestinal adenocarcinoma 1 follow site : Pancreatic Biliary Gastric Colorectal Esophageal Melanoma Ovarian cancer Astrocytoma brain tumor Not immediately eligible treatment would potentially curative lifeprolonging , opinion investigator Patients may candidate future bone marrow transplantation eligible No brain metastasis ( astrocytomas ) No clinically significant pleural effusion No complete tumor obstruction ( e.g. , bronchus , ureter , bowel ) PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 50100 % Life expectancy Not specify Hematopoietic WBC least 3,500/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count great 50,000/mm^3 Hematocrit stable without need transfusion ( epoetin alfa support allow ) Hepatic Bilirubin less 1.5 time upper limit normal ( ULN ) ( unless due Gilbert 's syndrome ) SGOT SGPT less 2 time ULN No active hepatitis B C Renal Creatinine clearance least 50 mL/min Cardiovascular No American Heart Association class III IV cardiac disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No active systemic infection require IV antibiotic PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Concurrent corticosteroid allow provided patient stable regimen Radiotherapy Not specify Surgery Not specify Other Recovered prior therapy No grade 24 toxicity More 3 week since prior antineoplastic and/or investigational therapy No concurrent systemic antineoplastic investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>adenocarcinoma extrahepatic bile duct</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
</DOC>